Loading stock data…
CYTK
$63.35-0.62 (-0.97%)
Market ClosedLast close May 1
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $63.35. The stock is currently near its 52-week high of $70.98, remaining 9.9% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why CYTK maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$63.35
Potential Upside
5%
Whystock Fair Value$66.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target$93.32+47.3%
Range$67.00 – $136.00
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
91.92%
Volume
Today's trading volume
2.21M
Recent News
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +60.93% and +74.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Why The Cytokinetics (CYTK) Story Is Shifting After Myqorzo Approvals And ACACIA Expectations
The fair value estimate for Cytokinetics has shifted from US$79.56 to US$92.94, signaling a fresh look at what the shares might be worth in updated models. That change lines up with recent analyst reactions to Myqorzo approvals, the ACACIA non obstructive HCM trial setup, and revised loss and margin timelines that feed into a wide price target range from the high US$60s to just above US$100. As you read on, you will see how these moving pieces shape the evolving story around risk,...
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference
Cytokinetics (NASDAQ:CYTK) executives outlined early commercialization efforts for MYQORZO and previewed several upcoming clinical and regulatory milestones during a fireside chat at Needham’s 25th Annual Healthcare Conference. Serge Belanger, a senior analyst at Needham & Company, moderated th
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus
FDA approves Cytokinetics' cardiac drug MYQORZO, a key product in its pipeline. Shortly after the approval, President and CEO Robert I. Blum sells a significant amount of company stock. Both events draw attention from investors tracking Cytokinetics (NasdaqGS:CYTK) and insider activity. Cytokinetics, listed on NasdaqGS:CYTK, focuses on muscle biology and treatments for serious cardiac conditions. The FDA approval of MYQORZO adds an approved therapy to its portfolio, which had centered on...